Ardelyx

ARDX

Market cap $1.56B

Michael Raab sold 41,666 shares directly on Feb. 24, 2026, for approximately $261,000 at a weighted-average price of $6.25 per share. The sale represented 2.19% of Raab's direct holdings at the time of the transaction.

DAYTONA BEACH, Fla. and WALTHAM, Mass.

Why Ardelyx's Offensive Strategy Doesn't Move The Needle

Ardelyx, Inc. delivered strong FY 2025 revenue growth, driven by Ibsrela, but missed on earnings due to sharply higher SG&A and R&D costs. Ibsrela's accelerating momentum underpins management's guidance for $410–$430M 2026 revenue and a $1B annual target by 2029, supported by patent protection through 2042. Xphozah revenue is declining and maturing, while heavy operational spend and net losses raise concerns about cost discipline and sustainability.

Ardelyx Inc. (NASDAQ: ARDX) shares are down during Friday's premarket session following a recent financial update for the fourth quarter of 2025.

Ardelyx, Inc. (ARDX) Q4 2025 Earnings Call Transcript

Although the revenue and EPS for Ardelyx (ARDX) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Ardelyx (ARDX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of $0.02. This compares to earnings of $0.02 per share a year ago.

IBSRELA revenue grew 73% in 2025 to $274.2 million and total revenues reached $407.3 million Patient-first XPHOZAH strategy preserved access and drove growth in total dispenses Development programs for new IBSRELA indication and next-generation NHE3 inhibitor launched Company is well capitalized to meet current business objectives Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update.

Besides Wall Street's top-and-bottom-line estimates for Ardelyx (ARDX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.